Advertisement
Advertisement

SLN

SLN logo

Silence Therapeutics Plc - ADR

11.95
USD
Sponsored
+0.23
+1.96%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

11.83

-0.12
-1.00%

Silence Therapeutics Plc - ADR Profile

About

Silence Therapeutics plc focuses on the discovery, development and delivery of novel RNA therapeutics in hematology, cardiovascular and other rare and metabolic indications. The Company's product candidate consist SLN124 for the treatment of iron overload disorders; SLN360 for the cardiovascular disease with high lipoprotein and SLN500 for the treatment of complement-mediated diseases which are in clinical stage. Silence Therapeutics plc is based in London, the United Kingdom.

Info & Links

CEO

Iain Ross

Headquarters

12 HAMMERSMITH GROVE, OFFICE 205
LONDON, X0 W6 7AP, UNITED KINGDOM

Industry

Medical Drugs

Sector

Medical

Website

www.silence-therapeutics.com

Auditor

PricewaterhouseCoopers LLP

Share holders

1,259

Employees

88

Silence Therapeutics Plc - ADR Statistics

Valuation Measures

Market Capitalization2

558.79M

Enterprise Value

553.17M

Enterprise Value/EBITDA(ttm)

-7.10

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

672.78

Price to Book(mrq)

11.43

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

70.98%

Operating Margin(ttm)

-8786.05%

Profit Margin(ttm)

-15888.67%

Return on Equity(ttm)

-105.34%

Return on Invested Capital(ttm)

-106.47%

Return on Assets(ttm)

-52.79%

Income Statement

Revenue(ttm)

839.00K

Revenue Per Share(ttm)

0.02

Gross Profit(ttm)

667.00K

EBITDA(ttm)3

-77.88M

Net Income Available to Common(ttm)

-75.04M

Diluted EPS(ttm)

-1.59

Share Statistics

Beta (5Y Monthly)

1.39

52-Week Change

122.12%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

47.23M

Dividend Yield

0.00%

Float4

45.82M

% Held by Insiders

3.00%

% Held by Institutions

98.73%

Balance Sheet

Total Cash(mrq)

70.08M

Total Cash Per Share(mrq)

1.48

Total Debt(mrq)

43.00K

Total Debt/Equity(mrq)

0.09%

Current Ratio(mrq)

9.83%

Quick Ratio(mrq)

9.83%

Book Value Per Share(mrq)

1.05

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.33

Free Cash Flow(ytd)

-15.60M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement